Gilead Sciences

5 Stories

Insurers Panic Over $1K-a-Day Wonder Drug

Congress demands to know why Sovaldi is so expensive

(Newser) - The FDA only approved Sovaldi in December, but the hepatitis C treatment is already setting records, with as much as $10 billion in sales expected in the first year alone. And why not? It has few side effects, cures 90% of patients, and, oh yeah, costs $1,000 a day.... More »

AIDS Drugs Slash Risk of Getting HIV in First Place

Pair of studies show minimum 60% drop in infection rate

(Newser) - The same antiretroviral drugs that treat HIV and AIDS can also be used to cut down the risk of contracting HIV in the first place, two new studies show. The dramatic results are just the latest evidence that AIDS drugs can be effective at prevention as well as treatment. While... More »

Global Patent Pool Scores 4 New AIDS Drugs

It's a major step to benefit poor nations battling disease

(Newser) - Gilead Sciences announced today that it will license four AIDS and hepatitis B drugs to an international patent pool, allowing cheap, generic versions to be produced for sale in low-income countries. The AIDS drugs, which include tenofovir and emtricitabine, represent a major upgrade on the treatments currently available in those... More »

After 20 Years, Scientists Crack HIV Puzzle

Enzyme integrase made visible for first time

(Newser) - After 40,000 failed trials and "painstakingly slow progress," scientists have solved a puzzle that stumped AIDS researchers for more than 20 years—and their findings could help develop more effective HIV drugs. The researchers at Harvard and Imperial College London grew a crystal that for the first... More »

Flu Spooks Street; Dow Off 51

Firms likely to be hurt by reaction to disease see shares drop

(Newser) - Swine flu worried investors but wasn’t enough to spark a full-scale sell-off today, the Financial Times reports. AMR, parent of American Airlines, Marriott, and Expedia fell as investors bet against firms that may be specifically hurt. Shares of Gilead Sciences, developer of Tamiflu, were up nearly 4%, however. The... More »

5 Stories

AROUND THE WEB